A phase 3 trial of intralesional cemiplimab in patients with early-stage cutaneous SCC, newly underway at GW and multiple other sites, will look at how well the immune checkpoint inhibitor ... from ...

The biotech sector remains one of the most dynamic areas of the market, driven by clinical breakthroughs, regulatory decisions, and disruptive inn ...